Compass Therapeutics Inc (NASDAQ: CMPX) kicked off on Monday, down -11.90% from the previous trading day, before settling in for the closing price of $2.69. Over the past 52 weeks, CMPX has traded in a range of $0.76-$4.08.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded -25.56%. With a float of $80.70 million, this company’s outstanding shares have now reached $137.82 million.
Let’s look at the performance matrix of the company that is accounted for 35 employees. In terms of profitability, gross margin is 74.8%, operating margin of -1501.0%, and the pretax margin is -1292.88%.
Compass Therapeutics Inc (CMPX) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Compass Therapeutics Inc is 41.64%, while institutional ownership is 38.87%.
Compass Therapeutics Inc (CMPX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -25.56% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 33.35% during the next five years compared to -104.70% drop over the previous five years of trading.
Compass Therapeutics Inc (NASDAQ: CMPX) Trading Performance Indicators
Take a look at Compass Therapeutics Inc’s (CMPX) current performance indicators. Last quarter, stock had a quick ratio of 14.96. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 385.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.36, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach -0.47 in one year’s time.
Technical Analysis of Compass Therapeutics Inc (CMPX)
Compass Therapeutics Inc (NASDAQ: CMPX) saw its 5-day average volume 0.59 million, a negative change from its year-to-date volume of 1.78 million. As of the previous 9 days, the stock’s Stochastic %D was 8.88%. Additionally, its Average True Range was 0.30.
During the past 100 days, Compass Therapeutics Inc’s (CMPX) raw stochastic average was set at 39.15%, which indicates a significant increase from 6.04% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 83.62% in the past 14 days, which was lower than the 104.42% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.66, while its 200-day Moving Average is $1.73. Nevertheless, the first resistance level for the watch stands at $2.56 in the near term. At $2.75, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.88. If the price goes on to break the first support level at $2.24, it is likely to go to the next support level at $2.11. The third support level lies at $1.92 if the price breaches the second support level.
Compass Therapeutics Inc (NASDAQ: CMPX) Key Stats
The company with the Market Capitalisation of 327.73 million has total of 138,283K Shares Outstanding. Its annual sales at the moment are 850 K in contrast with the sum of -49,380 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -10,480 K.
